Polysaccharides Patents (Class 536/55.1)
-
Publication number: 20120190644Abstract: Biomaterials obtainable by mixing the autocrosslinked derivative of hyaluronic acid (ACP) with the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers.Type: ApplicationFiled: August 25, 2010Publication date: July 26, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'este, Davide Renier
-
Publication number: 20120190098Abstract: Fluorophores derived from photoactivatable azide-pi-acceptor fluorogens or from a thermal reaction of an azide-pi-acceptor fluorogen with an alkene or alkyne are disclosed. Fluorophores derived from a thermal reaction of an alkyne-pi-acceptor fluorogen with an azide are also disclosed. The fluorophores can readily be activated by light and can be used to label a biomolecule and imaged on a single-molecule level in living cells.Type: ApplicationFiled: March 1, 2012Publication date: July 26, 2012Applicants: LELAND STANFORD JUNIOR UNIVERSITY, KENT STATE UNIVERSITYInventors: ROBERT J. TWIEG, WILLIAM E. MOERNER, SAMUEL J. LORD, NA LIU, REICHEL SAMUEL
-
Publication number: 20120171150Abstract: A pharmaceutical composition is provided that is useful for reducing sodium in the bloodstream of animals. In some embodiments, the pharmaceutical composition comprises a high-ion-affinity part and a substrate part. Additionally, methods of using the pharmaceutical composition and methods of treating diseases with the pharmaceutical composition are disclosed.Type: ApplicationFiled: January 5, 2011Publication date: July 5, 2012Inventor: Benjamin S. Metelits
-
Publication number: 20120148660Abstract: The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.Type: ApplicationFiled: February 7, 2008Publication date: June 14, 2012Applicant: Regents of the University of California, San Diego UCSD Technology Transfer OfficeInventors: Dennis A. Carson, Howard B. Cottam, Wolfgang Wrasidlo, Christina C.N. Wu, Gregory A. Daniels
-
Patent number: 8193325Abstract: The present invention relates a processing method for nano-miniaturizing chitosan of modifying property, which degrades the chitosan of high molecular weight down to the chitosan of middle and low molecular weight, then primarily nano-miniaturizes the interim chitosan by quaternary ammonium salt/synthesis, finally yield the nano-miniaturized chitosan of modified property by sol-gel method to have features in good biocompatibility and bioactivity to be served as additive material in products of cosmetics, medical treatment, hygiene, health care, biomedicine, agriculture, textile, food and so like so that not only the antiseptic, moisture-retentive and deodorizing capabilities can be promoted but also the processing cost can be reduced due to easiness of the mass production.Type: GrantFiled: December 31, 2008Date of Patent: June 5, 2012Assignee: Acelon Chemical and Fiber CorporationInventors: Wen-Tung Chou, Ming-Yi Lai, Kun-Shan Huang, Wei-Chun Chen
-
Publication number: 20120136073Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.Type: ApplicationFiled: November 15, 2011Publication date: May 31, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Zhiwei Yang, Parul Angrish, Xavier de Mollerat du Jeu, Kristin Wiederholt
-
Publication number: 20120135063Abstract: An object of the present invention is to provide a uronic acid-containing glucan or a modified product thereof. The glucuronic acid-containing glucan of the present invention is a glucuronic acid-containing glucan in which a glucuronic acid residue is bound to at least one non-reducing end of a glucan, and the glucan is a branched ?-1,4 glucan or a linear ?-1,4 glucan. The glucuronic acid-containing glucan of the present invention can be provided by allowing ?-glucan phosphorylase derived from Aquifex aeolicus VF5 to act on glucuronic acid-1-phosphate to thereby transfer a glucuronic acid residue to the non-reducing end of the receptor glucan.Type: ApplicationFiled: May 10, 2010Publication date: May 31, 2012Applicant: EZAKI GLICO CO., LTD.Inventors: Junichi Kadokawa, Takeshi Takaha, Akiko Kubo, Michiyo Yanase, Kayo Hosoya
-
Publication number: 20120129919Abstract: The present invention relates to a group of polycationic amphiphilic cyclooligosaccharides which, due to their molecular structure, may be used as molecular transporters to the interior of cells. Furthermore, the present invention also relates to the use of said compounds in the preparation of a medicament, to the use of this medicament for gene therapy and to a pharmaceutical composition that comprises one of said compounds.Type: ApplicationFiled: April 14, 2010Publication date: May 24, 2012Inventors: Carmen Ortiz Mellet, Alejandro Méndez Ardoy, Marta Gómez Garcia, Natalia Sevillano Trapero, Mª Dolores Girón González, Rafael Salto González, Francisco Santoyo González, José Manuel García Fernández
-
Publication number: 20120128741Abstract: The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.Type: ApplicationFiled: July 23, 2010Publication date: May 24, 2012Applicant: Carbylan Biosurgery, Inc.Inventors: David M. Gravett, George Y. Daniloff, Pingren He
-
Patent number: 8183229Abstract: Provided is a bone filling complex and method of preparing the same. The bone filling complex includes a matrix including a hydrogel-type hyaluronic acid derivative; and a bone derivative filling the matrix For example, the bone filling complex can be used to regenerate an injured alveolar bone.Type: GrantFiled: August 27, 2007Date of Patent: May 22, 2012Assignees: Megagen Implant Co., Ltd., Pohang University of Science and Technology Dept. of Advanced Materials Science & EngineeringInventors: Sei Kwang Hahn, Eun Ju Oh, Jung Kyu Park, Kwang Bum Park, Kyoung Ho Ryoo, Seok Kyu Choi, Dong Jun Yang, Hyun Wook An
-
Patent number: 8178511Abstract: Disclosed is a method for the amelioration of resorptive bone loss in osteopenia including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation.Type: GrantFiled: June 16, 2009Date of Patent: May 15, 2012Inventor: James D. Smith
-
Publication number: 20120116066Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.Type: ApplicationFiled: October 29, 2010Publication date: May 10, 2012Applicant: Reliable Biopharmaceutical CorporationInventors: Payal P. Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
-
Publication number: 20120107942Abstract: The present invention provides compounds and methods for rapid labeling of N-glycans, for example, rapid fluorescent labeling of N-glycans. In one aspect, the present invention provides fluorescent carbamate or thiocarbamate compounds. Upon contacting with N-glycans, the compounds undergo facile reactions with N-glycans to form fluorescent-labeled N-glycans.Type: ApplicationFiled: September 24, 2011Publication date: May 3, 2012Applicant: ProZyme, Inc.Inventor: TOMASZ BAGINSKI
-
Publication number: 20120107874Abstract: The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.Type: ApplicationFiled: November 29, 2011Publication date: May 3, 2012Applicant: Eureka Therapeutics, Inc.Inventors: Cheng Liu, Jingyi Xiang, Su Yan, Pei Wang, Wei Chan Tai
-
Patent number: 8163716Abstract: Disclosed is a method for the amelioration of osteophyte formation including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation.Type: GrantFiled: June 16, 2009Date of Patent: April 24, 2012Inventor: James D. Smith
-
Publication number: 20120088848Abstract: Methods and compositions for the generation of polypeptides having varied material properties are disclosed herein. Methods include means for initiating the polymerization of aminoacid-N-carboxyanhydride (NCA) monomer by combining the monomer with an amido-containing metallacycle, for making self assembling amphiphilic block copolypeptides and related protocols for adding oligo(ethyleneglycol) functionalized aminoacid-N-carboxyanhydrides (NCAs) to polyaminoacid chains. Additional methods include means of adding an end group to the carboxy terminus of a polyaminoacid chain by reacting an alloc-protected amino acid amide with a transition metal-donor ligand complex to forming an amido-amidate metallacycle for use in further polymerization reactions. Novel compositions for use in peptide synthesis and design including five and six membered amido-containing metallacycles and block copolypeptides are also disclosed.Type: ApplicationFiled: March 31, 2011Publication date: April 12, 2012Inventors: Timothy J. Deming, Miaoer Yu, Scott A. Curtin, Jungyeon Hwang, Michael D. Wyrsta, Andrew Nowak, Scott W. Seidel
-
Publication number: 20120082717Abstract: Disclosed herein is a complex, wherein micelles and/or liposomes dispersed in hyaluronic acids and/or hyaluronic acid derivatives, with a drug and/or functional material loaded in the micelles and/or the liposomes. The complex can release the drug and/or functional material in a controlled manner. Also, a multilayer using the complex, and a device coated with the multilayer are disclosed herein.Type: ApplicationFiled: June 4, 2010Publication date: April 5, 2012Applicants: SNU R&DB FOUNDATION, ILJIN MATERIALS CO., LTD.Inventors: Kook Heon Char, Sai Bom Park, Jin Hwa Seo, Sang Beom Kim, Chong Su Seo
-
Publication number: 20120083006Abstract: The present invention relates to immobilization compounds (I), immobilization products and preparations thereof as well as methods and uses for the identification of kinase interacting compounds or for the purification or identification of kinase proteins.Type: ApplicationFiled: March 31, 2010Publication date: April 5, 2012Applicant: Cellzone AGInventors: Nigel Ramsden, Jeremy Major, John Harrison, Daniel Leggate, Paola Grandi
-
Patent number: 8148335Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.Type: GrantFiled: December 22, 2006Date of Patent: April 3, 2012Assignee: Children's Hospital & Research Center OaklandInventors: Gregory R. Moe, Charles Paul Plested
-
Publication number: 20120058161Abstract: Described herein are alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated and alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including use for ocular or ophthalmic treatment.Type: ApplicationFiled: November 23, 2011Publication date: March 8, 2012Applicant: University of Utah Research FoundationInventors: Glenn D. Prestwich, Jianxing Zhang, Thomas P. Kennedy, Narayanam V. Rao
-
Publication number: 20120046435Abstract: The present invention relates to novel carbohydrate polyether compositions that are soluble in aqueous media and particularly to carbohydrate polyether compositions exhibiting reverse thermogelation properties in aqueous media. Also, since the carbohydrate polyethers of the present invention can be conveniently controlled with respect to functionality, molecular weight, polydispersity index, microstructure and tertiary structure, they can be customized for use in a variety of applications.Type: ApplicationFiled: August 8, 2011Publication date: February 23, 2012Inventor: Alexander A. GORKOVENKO
-
Publication number: 20120035321Abstract: The present disclosure relates to compounds and medical devices activated with a solvophobic material functionalized with a first reactive member and methods of making such compounds and devices.Type: ApplicationFiled: February 22, 2010Publication date: February 9, 2012Inventors: Sébastien Ladet, Philippe Gravagna
-
Publication number: 20120034462Abstract: Hair-like shaped crosslinked hydrogels and methods for preparing such crosslinked hydrogels and are provided.Type: ApplicationFiled: October 14, 2011Publication date: February 9, 2012Applicant: ALLERGAN, INC.Inventors: Dimitrios Stroumpoulis, Karina Heredia Guillen
-
Publication number: 20120035128Abstract: Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C1-10 hydrocarbon group, Y is a polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R2, with R2 being a C1-23 hydrocarbon group. The hydrogel has excellent viscoelasticity and can be injected into a predetermined location with an injection device such as a syringe, and thus can be advantageously used as a medical gel or an adhesion barrier.Type: ApplicationFiled: April 19, 2010Publication date: February 9, 2012Applicant: TEIJIN LIMITEDInventors: Hiroaki Kaneko, Masaya Ito
-
Patent number: 8110677Abstract: This invention relates to a method of extracting crude polysaccharide by microwave-assisted from Artemisia sphaerocephala seed de-oiling dregs. In particular, the invention comprising: microwave-assisted extraction, enzymatic hydrolysis, dialysis et. al. It provides a technique whereby the polysaccharide can be extracted effectively, in a relatively short period of time (20-30 min) with respect to conventional extraction methods and allows for an enhanced extraction yield (more than 30%). Furthermore, the invention also allows for the extraction of material with less solvent consumption, good reproducibility, excellent solubility, energy conservation, environmental protection, and showed great potential for efficient sample preparation and large-scale industrial application in the near future. With great resource advantage of Artemisia sphaerocephala in China, the invention has bright perspectives in promoting local economic development.Type: GrantFiled: February 24, 2009Date of Patent: February 7, 2012Assignee: Northwest Normal UniversityInventors: Ji Zhang, Junlong Wang, Yiqian Wu, Jian Yao, Yunpu Wang, Junyu Liang, Yanan Zhang, Xiaodong Wang, Xiaoqing Xu
-
Patent number: 8105391Abstract: Provided herein are a method, which comprises implanting in a patient an implantable device comprising a coating that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.Type: GrantFiled: April 1, 2010Date of Patent: January 31, 2012Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Lothar W. Kleiner, Connie S. Kwok
-
Publication number: 20120022016Abstract: The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.Type: ApplicationFiled: July 18, 2011Publication date: January 26, 2012Inventor: Donald L. Barbeau
-
Patent number: 8097446Abstract: This disclosure presents embodiments of novel strains of Staphylococcus aureus that through genetic engineering produce type 5 capsular polysaccharide at greater levels than Staphylococcus aureus strain Reynolds.Type: GrantFiled: March 5, 2009Date of Patent: January 17, 2012Assignee: Board of Trustees of the University of ArkansasInventors: Chia Y. Lee, Thanh T. Luong
-
Patent number: 8092732Abstract: The present invention provides a processing method of the natural cellulose fiber with feature for enhancing the capability of antifungi, antibacteria and deodorization. The procedure is that firstly modify and reduce the properties of the natural chitosan of high polymer material to nanometer scale; secondly dunk the chitosan into the syrup-like mixture of wood pulp and NMMO solvent to yield quasi-dope; thirdly dehydrate the quasi-dope of paste mixture to form the mud-like dope; fourthly spin the dope by dryjet wet spinning method; fifthly regenerate the filament in coagulation bath, water rinse and dry; finally water rinse, dry, apply the lubricant to finish. The water soluble chitosan, which has been treated by property modification and reduced to nanometer scale, can effectively and completely solve in the cellulose of low DP to offer wider extent of selection in the DP and better flexibility of adding percentage in content of modified chitosan.Type: GrantFiled: December 31, 2008Date of Patent: January 10, 2012Assignee: Acelon Chemical and Fiber CorporationInventors: Wen-Tung Chou, Ming-Yi Lai, Kun-Shan Huang
-
Publication number: 20110319357Abstract: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW.Type: ApplicationFiled: June 20, 2011Publication date: December 29, 2011Applicant: Novozymes Biopolymer A/SInventors: Kristoffer Tommeraas, Corinne Eenschooten
-
Publication number: 20110305744Abstract: A preparation for vaginal and rectal use comprising hyaluronic acid, with an average particle size comprised between about 50 micrometers and about 200 micrometers and a molecular weight comprised between about 1,000,000 Da and about 1,800,000 Da.Type: ApplicationFiled: September 8, 2010Publication date: December 15, 2011Applicant: FARMA-DERMA SRLInventor: Vincenzo Russo
-
Patent number: 8071757Abstract: A hyaluronic acid derivative, and methods of producing and using said derivative, the derivative comprising n repeating units and having the general structural formula (I), wherein, in at least one repeating unit, one or more of R1, R2, R3, R4 comprises an etherbound aryl/alkyl sulfone having the general structural formula (II), wherein R comprises an alkyl- or aryl-group, and otherwise R1, R2, R3, R4 are hydroxyl groups, OH.Type: GrantFiled: March 2, 2007Date of Patent: December 6, 2011Assignee: Novozymes Biopharma DK A/SInventors: Corinne Eenschooten, Morten Würtz Christensen
-
Patent number: 8071570Abstract: The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.Type: GrantFiled: May 9, 2011Date of Patent: December 6, 2011Assignee: Aventis Pharma S.A.Inventors: Christian Viskov, Vesna Biberovic, Pierre Mourier, Luc Grondard
-
Publication number: 20110288283Abstract: The invention provides a process for the production of a composition comprising a glycosaminoglycan, said process comprising subjecting a homogenate of glycosaminoglycan-containing animal material to chromatography using a chromatographic matrix in the form of a membrane adsorber.Type: ApplicationFiled: July 15, 2009Publication date: November 24, 2011Applicant: HEPMARIN ASInventor: Ragnar Flengsrud
-
Publication number: 20110287067Abstract: Described herein is the synthesis of reinforced adhesive complex coacervates and their use thereof. The reinforced adhesive complex coacervates are composed of (a) at least one polycation, (b) at least one polyanion, and (c) a reinforcing component. The adhesive complex coacervates described herein can be subsequently cured to produce strong, cohesive adhesives. The reinforced adhesive complex coacervates have several desirable features when compared to conventional adhesives. The reinforced adhesive complex coacervates are effective in wet or underwater applications. The reinforced adhesive complex coacervates described herein, being phase separated from water, can be applied underwater without dissolving or dispersing into the water. The reinforced adhesive complex coacervates have numerous biological applications as bioadhesives and bioactive delivery devices.Type: ApplicationFiled: May 24, 2011Publication date: November 24, 2011Inventor: Russell John STEWART
-
Patent number: 8049002Abstract: Processes for the synthesis of lipochitooligosaccharides were developed. A fully acylated oligoglucosamine precursor is prepared and reacted with a glucosamine monomer that has an amine protecting phthaloyl group. With removal of the phthaloyl group, a fatty acid may be added on the terminal glucosamine unit, forming a lipochitooligosaccharide. The processes can be adapted for use on a commercial scale.Type: GrantFiled: May 7, 2009Date of Patent: November 1, 2011Assignee: E.I. du Pont de Nemours and CompanyInventor: Subramaniam Sabesan
-
Publication number: 20110263724Abstract: The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.Type: ApplicationFiled: September 2, 2009Publication date: October 27, 2011Inventors: Geoffrey C. Gurtner, Kenneth N. Horne, Jayakumar Rajadas
-
Publication number: 20110245196Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.Type: ApplicationFiled: October 16, 2008Publication date: October 6, 2011Inventors: Vito Ferro, Karoli Tomislav, Liu Ligong, Handley Paul Newton, Johnstone Kenneth David, Norbert Wimmer, Hammond Edward Timothy
-
Publication number: 20110244520Abstract: The invention relates to the field of recombinant DNA technology for the production of chondroitin, including the production of chondroitin sulfate via a combination of recombinant bacterial fermentation and post-fermentation sulfation.Type: ApplicationFiled: March 1, 2011Publication date: October 6, 2011Inventors: Daniel H. Doherty, Craig A. Weaver, Kentaro Miyamoto, Toshikazu Minamisawa
-
Patent number: 8026221Abstract: A method for detecting a Norwalk-Like Virus (NLV) in a biological sample, comprising the steps of: obtaining a biological sample suspected of containing a NLV; contacting the biological sample with at least one human histo-blood group antigen to allow formation of a complex of the NLV with the antigen; and detecting the antigen-NLV complex. The antigen-NLV complex can be detected by contacting the NLV-antigen complex with a NLV antibody that binds at an epitope of the NLV, and detecting the NLV antibody. The invention also includes a method for identifying compounds, and the compounds, that can inhibit the binding between a Norwalk-Like Virus (NLV) and a histo-blood group antigen.Type: GrantFiled: February 29, 2008Date of Patent: September 27, 2011Assignees: Children's Hospital Medical Center, INSERMInventors: Xi Jiang, Jacques Le Pendu
-
Publication number: 20110230652Abstract: This invention provides compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond.Type: ApplicationFiled: February 22, 2011Publication date: September 22, 2011Inventor: Saul YEDGAR
-
Publication number: 20110224423Abstract: The invented inositol and trehalose derivatives, prepared by introducing multiple units of the guanidine group to the backbone molecules, show excellent blood-brain barrier permeability, and accordingly, it can be easily transported to the brain tissues and utilized for the treatment of neurodegenerative diseases such as Alzheimer's disease and Huntington's disease.Type: ApplicationFiled: March 23, 2009Publication date: September 15, 2011Inventors: Sung-Kee Chung, Woo Sirl Lee, Boram Kim, Jungkyun Im, Subhash C. Ghosh
-
Publication number: 20110217750Abstract: An activatable functionalised Nth generation dendrimer having: a core comprising a first monomer having at least two carboxylic acid functional groups; and N successive generations, where N=0 to 10, wherein each generation comprises: a second monomer having at least two alcohol functional groups, wherein at least one alcohol group is bonded to a carboxylic acid group of the first monomer of the prior generation, and an additional first monomer attached to a second alcohol function group of said second monomer of that generation; and the final generation having attached thereto at said second alcohol functional group of said second monomer, a moiety having a dicarboxylic acid functional group, activatable by treatment with a carboxylic acid activating reagent such that reactivity of the carboxylic acid functional group is increased. The dendrimer, when activated, may be used in applications such as polymer crosslinking and/or nanoshell production.Type: ApplicationFiled: March 19, 2009Publication date: September 8, 2011Applicant: NATIONAL UNIVERSITY OF IRELAND, GALWAYInventors: Abhay Pandit, Gildas Rethore, Hemantkumar Naik
-
Patent number: 8012907Abstract: The present invention relates to cationic, gel forming, guanidinated polysaccharides of Formula I, their use as absorbent materials, and to processes for producing same: Formula I wherein Z1, Z2, and Z3 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, C5-C7 cycloalkyl, and benzyl; and m is an integer ranging from 1 to 2,000,000. The absorbent guanidinated polysaccharides of Formula I have absorbent properties suitable for use in personal care products.Type: GrantFiled: September 14, 2005Date of Patent: September 6, 2011Assignee: Archer Daniels Midland CompanyInventor: Mohammed Berrada
-
Publication number: 20110212901Abstract: The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): wherein R1, R2, R3, R4, Z, n, Ra, Y, and X1 are as defined in the specification.Type: ApplicationFiled: November 5, 2009Publication date: September 1, 2011Applicants: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kazunari Akiyoshi, Takashi Nakai, Tai Hirakura, Tsuyoshi Shimoboji
-
Patent number: 8008275Abstract: A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and ??T cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and viral infections.Type: GrantFiled: October 2, 2008Date of Patent: August 30, 2011Inventor: Gradimir Misevic
-
Publication number: 20110206772Abstract: The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.Type: ApplicationFiled: May 28, 2009Publication date: August 25, 2011Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Bruce Panilaitis, Michael Mercaldi, Hanna Dams-Kozlowska
-
Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
Patent number: 8003782Abstract: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades.Type: GrantFiled: February 1, 2000Date of Patent: August 23, 2011Assignee: Dermal Research Laboratories, Inc.Inventors: Harold G. Brown, Carol A. Cooper, Kristina J. Hennessy, Karen K. Brown -
Publication number: 20110166339Abstract: ?-Lactosamine hydrochloride, substantially free of ?-lactosamine hydrochloride; a method of preparing ?-lactosamine hydrochloride monohydrate from an anomeric mixture of lactosamine hydrochloride, including: preparing a solution including the anomeric mixture of lactosamine hydrochloride, water and at least one water-miscible organic solvent at a temperature of 0-100° C., and cooling the solution to cause crystallisation of ?-lactosamine hydrochloride monohydrate; a method of preparing anhydrous ?-lactosamine hydrochloride; and use of ?-lactosamine hydrochloride as a food supplement or intermediate in synthesis.Type: ApplicationFiled: July 15, 2009Publication date: July 7, 2011Applicant: GLYCOM A/SInventors: Gyula Dekany, Karoly Agoston, Istvan Bajza, Marie Bøjstrup, Ignacio Fegueroa Pérez, Lars Kröger, Christoph H. Röhrig
-
Publication number: 20110142876Abstract: Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM197 (a non-toxic variant of diphtheria toxin) and tetanus toxoid, as carrier proteins.Type: ApplicationFiled: June 12, 2009Publication date: June 16, 2011Inventors: Francesca Micoli, Paolo Costantino, Francesco Berti